Catheter Precision

No. Catheter Precision, Inc. is a publicly listed medical device company that sells surgical closure products and cardiac mapping tools. It files 10-K and 10-Q reports with the SEC and operates as an operating business, not as a manager of private capital for a single family or external investors.

The company sells LockeT, a suture retention device used to close percutaneous skin incisions following interventional procedures. Its legacy intellectual property relates to a cardiac electrophysiology system designed to locate the origin of ventricular arrhythmias, though commercialization of that product line remains limited.

The company was formerly known as Ra Medical Systems. In 2023 it rebranded to Catheter Precision, and in January 2025 it completed a 1-for-10 reverse stock split. Both moves were tied to regaining compliance with NYSE American continued listing standards after the stock price fell below the exchange's minimum threshold (per SEC filings).

None are disclosed in its public filings. The company deploys its cash into operating activities — clinical trials, regulatory approvals, and sales infrastructure — rather than into third-party funds, co-investments, or venture portfolios. It has no known alternative investment program.

David Jenkins has served as Chief Executive Officer through the transition from Ra Medical Systems. The board and officer roster is publicly available in the company's annual proxy statement, and no individuals from private-wealth or family-office backgrounds appear in leadership roles.